The Effectiveness of a Computer Reminder System for Laboratory Monitoring of Metabolic Syndrome in Schizophrenic Outpatients Using Second-generation Antipsychotics

Pharmacopsychiatry

Volumn 48, Issue 1, 2015, Pages 25-29

  Lai, C L ^a   Chan, H Y ^a,b   Pan, Y J ^c,d   Chen, C H ^a  

^a Taoyuan Psychiatric Center   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

antipsychotics; computer reminder system; metabolic syndrome; schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZOTEPINE;

ADULT; AMBULATORY CARE; ARTICLE; CARDIOMETABOLIC RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMPUTER REMINDER SYSTEM; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT; OUTPATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALIFIED PATIENT VISIT; REMINDER SYSTEM; SCHIZOPHRENIA; CHEMICALLY INDUCED; FACTUAL DATABASE; LONGITUDINAL STUDY; METABOLIC DISEASES; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TAIWAN;

ADULT; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METABOLIC DISEASES; MIDDLE AGED; OUTPATIENTS; REMINDER SYSTEMS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TAIWAN;

EID: 84928405571     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1394396     Document Type: Article

References (33)

1. Haupt D. W., Newcomer J. W. Hyperglycemia and antipsychotic medications. J Clin Psychiatry: 2001; 62 27 15 26
2. Lindenmayer J. P., Nathan A. M., Smith R. C. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry: 2001; 62 23 30 38
3. Henderson D. C. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs: 2002; 16 77 89
4. Liebzeit K. A., Markowitz J. S., Caley C. F. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol: 2001; 11 25 32
5. Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-euro-american societies. Clin Neuropharmacol: 2012; 35 141 147
6. Nasrallah H. A., Newcomer J. W. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol: 2004; 24 01 7 14
7. Morrato E. H., Cuffel B., Newcomer J. W. et al. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol: 2009; 29 26 32
8. Expert G. 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry: 2004; 184 112 114
9. De Nayer A., De Hert M., Scheen A. et al. Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale: 2007; 33 197 202
10. Mitchell A. J., Delaffon V., Vancampfort D. et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med: 2012; 42 125 147
11. Newcomer J. W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry: 2007; 68 01 20 27
12. Harris M. I., Eastman R. C., Cowie C. C. et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care: 1999; 22 403 408
13. Ziemer D. C., Doyle J. P., Barnes C. S. et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med: 2006; 166 507 513
14. Mohan A. V., Phillips LS. Clinical inertia and uncertainty in medicine. JAMA: 2011; 306 383
15. Phillips L. S., Branch W. T., Cook C. B. et al. Clinical inertia. Ann Intern Med: 2001; 135 825 834
16. Martens J. D., van der Aa A., Panis B. et al. Design and evaluation of a computer reminder system to improve prescribing behaviour of GPs. Stud Health Tech Informat: 2006; 124 617 623
17. McDonald C. J., Hui S. L., Smith D. M. et al. Reminders to physicians from an introspective computer medical record. A two-year randomized trial. Ann Intern Med: 1984; 100 130 138
18. Wilbur L., Huffman G., Lofton S. et al. The use of a computer reminder system in an emergency department universal HIV screening program. Ann Emerg Med: 2011; 58 01 71 73
19. Nilasena D. S., Lincoln M. J. A computer-generated reminder system improves physician compliance with diabetes preventive care guidelines. Proc Annu Symp Comput Appl Med Care: 1995; 640 645
20. Agostini J. V., Zhang Y., Inouye S. K. Use of a computer-based reminder to improve sedative-hypnotic prescribing in older hospitalized patients. J Am Geriatr Soc: 2007; 55 43 48
21. Del Monte M. T., Bostwick J. R., Bess J. D. et al. Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics. J Clin Pharm Ther: 2012; 37 668 673
22. Baptista T., Molina M. G., Martinez J. L. et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry: 1997; 30 256 262
23. Baptista T., Alastre T., Contreras Q. et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry: 1997; 30 250 255
24. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs: 2005; 19 01 1 93
25. Haupt D. W., Newcomer J. W. Hyperglycemia and antipsychotic medications. J Clin Psychiatry: 2001; 62 27 15 26 discussion 40-41
26. Wetterling T., Mussigbrodt H. E. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol: 1999; 19 316 321
27. Wu R. R., Zhao J. P., Liu Z. N. et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology: 2006; 186 572 578
28. Huang M. C., Lu M. L., Tsai C. J. et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand: 2009; 120 274 280
29. Leucht S., Cipriani A., Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet: 2013; 382 951 962
30. Bungard T. J., Ghali W. A., Teo K. K. et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med: 2000; 160 41 46
31. Ziemer D. C., Doyle J. P., Barnes C. S. et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med: 2006; 166 507 513
32. Phillips L. S., Ziemer D. C., Doyle J. P. et al. An endocrinologist-supported intervention aimed at providers improves diabetes management in a primary care site: improving primary care of African Americans with diabetes (IPCAAD) 7. Diabetes Care: 2005; 28 2352 2360
33. Perlin J. B., Pogach L. M. Improving the outcomes of metabolic conditions: managing momentum to overcome clinical inertia. Ann Intern Med: 2006; 144 525 527